Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Conditions: Non-Alcoholic Fatty Liver Disease Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Oral Tablet Sponsors: Ann& Robert H Lurie Children ' s Hospital of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial FDG-PET Imaging
Conditions: Myocardial Suppression Interventions: Other: Fast + High-fat low-carbohydrate diet; Combination Product: Fast + Empagliflozin Sponsors: Matthieu Pelletier-Galarneau, MD MSc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging
Conditions: Myocardial Suppression Interventions: Other: Fast + High-fat low-carbohydrate diet; Combination Product: Fast + Empagliflozin Sponsors: Matthieu Pelletier-Galarneau, MD MSc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
Conditions: STEMI; No-Reflow Phenomenon Interventions: Drug: Empagliflozin 25 milgrams (Mg); Drug: Empagliflozin 10 Mg; Drug: Placebo 25 Mg; Drug: Placebo 10 Mg Sponsors: Instituto Nacional de Cardiologia Ignacio Chavez Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Conditions: Healthy Volunteers Interventions: Drug: HD-P023; Drug: Teneligliptin; Drug: Empagliflozin Sponsors: Handok Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers
Conditions: Healthy Volunteer Interventions: Drug: Generic empagliflozin 25 mg film-coated tablets Sponsors: International Bio service Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
Conditions: Coronary Artery Disease Interventions: Drug: Empagliflozin 10 MG; Drug: Vildagliptin 50 MG Sponsors: Damanhour University; Tanta University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
Conditions: Healthy Vollunteer Interventions: Drug: Empagliflozin 10 mg tablets; Drug: JARDIANCE ® Sponsors: Pharma Nueva Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
Conditions: Hematocrit Change; Cardiovascular Prevention; Empagliflozin; SGLT2-Inhibitors; Tissue Oxygenation Interventions: Drug: Empagliflozin10Mg Tab Sponsors: Aristotle University Of Thessaloniki Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
JARDIANCE ® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
Conditions: Kidney Disease, Chronic Interventions: Drug: JARDIANCE ® Sponsors: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
Conditions: Coronary Artery Disease; Atherosclerosis, Coronary Interventions: Drug: Statin; Drug: Aspirin tablet; Drug: Nexlizet; Drug: LEQVIO; Drug: Vascepa; Drug: Jardiance; Drug: Colchicine Sponsors: University of Louisville Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
Conditions: Adult Congenital Heart Disease; Heart Failure Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Sponsors: Anita Saraf; The Pittsburgh Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease
Conditions: Heart Failure With Reduced Ejection Fraction; End Stage Renal Disease on Dialysis Interventions: Drug: Empagliflozin 25 MG; Drug: Placebo Sponsors: National Taiwan University Hospital; Shin Kong Wu Ho-Su Memorial Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
Conditions: Heart Failure With Preserved Ejection Fraction; End Stage Renal Disease on Dialysis Interventions: Drug: Empagliflozin 25 MG; Drug: Placebo Sponsors: National Taiwan University Hospital; Shin Kong Wu Ho-Su Memorial Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg
Conditions: Healthy Subjects Interventions: Drug: Empagliflozin-Test product; Drug: Empagliflozin-Reference product Sponsors: Bio-innova Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
